• Hypertension risk higher with radical vs partial nephrectomy for renal tumors

    Stroke risk doubled in patients normotensive at baseline.

  • Bevacizumab biosimilar gets FDA nod for 5 cancer types

    Bevacizumab-bvzr could offer a cheaper alternative to the reference product.

  • Long-term surveillance safe for small renal tumors in elders

    Rate of progression is low at 55-month follow-up.

  • Early unclamping reduces partial nephrectomy complications

    Despite use by experienced surgeons, technique is largely unstudied.

  • Checkpoint inhibitors are rapidly adopted in clinical practice

    A wide gap in patient characteristics exists in the real-world compared with clinical trials.

  • RCC: targeted therapy benefits elderly

    Targeted therapy has survival advantage despite greater patient comorbidity and disability.

  • Renal cancer: limited benefit for nivolumab in brain metastases

    Focal brain therapy improves intracranial PFS.

  • ASCO 2019 — Tumor markers for advanced renal cell carcinoma may inform personalized therapy

    Cohorts from the JAVELIN Renal 101 trial are investigated for an association between tumor markers and outcomes.

  • Renal mass biopsy complications are rare

    Nondiagnostic findings were common.

  • AKI impairs long-term functional recovery after partial nephrectomy

    A study from Memorial Sloan Kettering Cancer Center.

  • FDA approves avelumab-axitinib for frontline RCC

    Approval is based on phase 3 JAVELIN Renal 101 study.

  • NICE approves nivolumab with ipilimumab for renal cancer

    Nivolumab with ipilimumab approved for use within the Cancer Drugs Fund for untreated advanced renal cell carcinoma

  • Metastatic kidney cancer: frontline atezolizumab-bevacizumab tops sunitinib in phase 3

    Data from IMmotion151.

  • FDA approves pembrolizumab-axitinib for renal cell carcinoma

    Approval is based on phase 3 KEYNOTE-426 study.

  • NICE decision on nivolumab with ipilimumab for renal cancer

    The treatment will be available within the Cancer Drugs Fund

  • Renal cancer: add-on dalantercept with axitinib fails phase 2 trial

    DART trial shows no PFS benefit in advanced clear-cell renal carcinoma.

  • Metastatic renal cancer: benefits of cytoreductive nephrectomy

    Survival benefit seen in patients with thrombus above the diaphragm.

  • Load more